Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
GK.2.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
C.13NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
B.1.1.59NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
C.38NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BA.2.10.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BA.1.1.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
AY.43.4 (Delta)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BQ.1.25.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
JN.1.42NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
JN.1.50.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BA.5.2.54NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
DR.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BA.5.2.59NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BF.15NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
XBB.3.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
ED.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BQ.1.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
CA.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BN.1.9NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BQ.1.28NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
DG.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BA.5.2.31NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
B.1.232NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BA.5.1.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
DE.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BQ.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
XEBNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
B.1.188ORF1abChan-ORF1abGTGTGATGTTGAWATGACATGGTC2441.671635316330R-4427.27China
B.1.267ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-4436.15Germany
CY.2NNIH-TH_NCCCCACTGCGTTCTCCATT1957.892837628358R-4438.27Thailand
XBB.2.11.1SChan-SCCTACTAAATTAAATGATCTCTGCTTTACT30302271222741F-4477.88China
B.45SChan-SCCTACTAAATTAAATGATCTCTGCTTTACT30302271222741F-4477.88China
B.1.258.7SChan-SCCTACTAAATTAAATGATCTCTGCTTTACT30302271222741F-4477.88China
AY.4.10 (Delta)NHKU-NCGAAGGTGTGACTTCCATG1952.632925429236R-4478.8Hong Kong
B.1.177.26NHKU-NCGAAGGTGTGACTTCCATG1952.632925429236R-4478.8Hong Kong
B.1.1.371NHKU-NCGAAGGTGTGACTTCCATG1952.632925429236R-4478.8Hong Kong
AY.121.1 (Delta)NHKU-NCGAAGGTGTGACTTCCATG1952.632925429236R-4478.8Hong Kong
Q.6 (Alpha)NHKU-NCGAAGGTGTGACTTCCATG1952.632925429236R-4478.8Hong Kong
P.7NHKU-NCGAAGGTGTGACTTCCATG1952.632925429236R-4478.8Hong Kong
AY.79 (Delta)NHKU-NCGAAGGTGTGACTTCCATG1952.632925429236R-4478.8Hong Kong
B.1.160.27NHKU-NCGAAGGTGTGACTTCCATG1952.632925429236R-4478.8Hong Kong
B.1.177.68NHKU-NCGAAGGTGTGACTTCCATG1952.632925429236R-4478.8Hong Kong
B.1.165NHKU-NCGAAGGTGTGACTTCCATG1952.632925429236R-4478.8Hong Kong
B.1.444NHKU-NCGAAGGTGTGACTTCCATG1952.632925429236R-4478.8Hong Kong
P.1.9 (Gamma)NHKU-NCGAAGGTGTGACTTCCATG1952.632925429236R-4478.8Hong Kong
AY.29.2 (Delta)NHKU-NCGAAGGTGTGACTTCCATG1952.632925429236R-4478.8Hong Kong
N.8NHKU-NCGAAGGTGTGACTTCCATG1952.632925429236R-4478.8Hong Kong
B.1.160.20ORF1abChan-ORF1abCGCATACAGTCTTRCAGGCT20501622016239F-4484.57China
B.1.160.19ORF1abChan-ORF1abCGCATACAGTCTTRCAGGCT20501622016239F-4484.57China
B.1.160.12ORF1abChan-ORF1abCGCATACAGTCTTRCAGGCT20501622016239F-4484.57China
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used